论文部分内容阅读
目的探讨泛福舒联合布地奈德对反复呼吸道感染支气管炎患儿细胞炎症因子水平的影响。方法选取82例反复呼吸道感染支气管炎患儿为研究对象,随机分为观察组和对照组,每组41例。两组患儿均接受吸氧、抗感染、祛痰、退热、止咳、全身用糖皮质激素等常规对症治疗,对照组患儿在此基础上给予吸入布地奈德混悬液雾化吸入治疗,观察组在对照组基础上口服泛福舒胶囊治疗。观察两组临床治疗疗效,比较两组治疗前后细胞炎症因子水平及治疗期间不良反应发生情况。结果观察组总有效率为95.12%显著高于对照组78.05%(P<0.05)。两组治疗前各项炎症因子水平比较无统计学意义(P>20.05),治疗后IL-4、IL-6、CRP、TNF-α水平均较治疗前均显著降低(P<0.01),观察组治疗后IL-4、IL-6、CRP、TNF-α依次为(29.82±6.19)ng/ml、(44.72±11.94)pg/m L、(8.00±1.32)mg/L、(7.69±1.71)ng/ml,降低幅度均明显高于较对照组(P<0.05)。两组患儿治疗期间均未见明显的不良反应。结论泛福舒联合布地奈德治疗反复呼吸道感染支气管炎临床效果较好,可显著降低患儿相关细胞炎症因子水平,安全可靠。
Objective To investigate the effect of pan Fu Shu combined with budesonide on the level of inflammatory cytokines in children with recurrent respiratory tract infections of bronchitis. Methods 82 cases of children with recurrent respiratory tract infections bronchitis were randomly divided into observation group and control group, with 41 cases in each group. The two groups of children received routine symptomatic treatment of oxygen, anti-infective, expectorant, antipyretic, cough-reducing and systemic glucocorticoid. The control group received inhaled budesonide suspension inhalation therapy The observation group was treated with Pan Fu Shu capsule on the basis of the control group. The clinical curative effect of the two groups was observed. The levels of inflammatory cytokines in the two groups before and after treatment were compared, and the incidence of adverse reactions during the treatment were compared. Results The total effective rate in observation group was 95.12%, significantly higher than 78.05% in control group (P <0.05). The levels of IL-4, IL-6, CRP and TNF-α in the two groups before treatment were significantly lower than those before treatment (P <0.01) The levels of IL-4, IL-6, CRP and TNF-α were (29.82 ± 6.19) ng / ml, (44.72 ± 11.94) pg / m L, (8.00 ± 1.32) mg / L, (7.69 ± 1.71 ) ng / ml, were significantly lower than the control group (P <0.05). No significant adverse reactions were observed in both groups during treatment. Conclusion Pan Fu Shu combined with budesonide in the treatment of recurrent respiratory tract infections bronchitis better clinical results, can significantly reduce the level of inflammatory cytokines in children with relevant, safe and reliable.